Your browser doesn't support javascript.
loading
Clinical targeting of HIV capsid protein with a long-acting small molecule.
Link, John O; Rhee, Martin S; Tse, Winston C; Zheng, Jim; Somoza, John R; Rowe, William; Begley, Rebecca; Chiu, Anna; Mulato, Andrew; Hansen, Derek; Singer, Eric; Tsai, Luong K; Bam, Rujuta A; Chou, Chien-Hung; Canales, Eda; Brizgys, Gediminas; Zhang, Jennifer R; Li, Jiayao; Graupe, Michael; Morganelli, Philip; Liu, Qi; Wu, Qiaoyin; Halcomb, Randall L; Saito, Roland D; Schroeder, Scott D; Lazerwith, Scott E; Bondy, Steven; Jin, Debi; Hung, Magdeleine; Novikov, Nikolai; Liu, Xiaohong; Villaseñor, Armando G; Cannizzaro, Carina E; Hu, Eric Y; Anderson, Robert L; Appleby, Todd C; Lu, Bing; Mwangi, Judy; Liclican, Albert; Niedziela-Majka, Anita; Papalia, Giuseppe A; Wong, Melanie H; Leavitt, Stephanie A; Xu, Yili; Koditek, David; Stepan, George J; Yu, Helen; Pagratis, Nikos; Clancy, Sheila; Ahmadyar, Shekeba.
Afiliação
  • Link JO; Gilead Sciences, Foster City, CA, USA.
  • Rhee MS; Gilead Sciences, Foster City, CA, USA.
  • Tse WC; Gilead Sciences, Foster City, CA, USA.
  • Zheng J; Vir Biotechnology Inc, San Francisco, CA, USA.
  • Somoza JR; Gilead Sciences, Foster City, CA, USA.
  • Rowe W; Gilead Sciences, Foster City, CA, USA.
  • Begley R; Gilead Sciences, Foster City, CA, USA.
  • Chiu A; Gilead Sciences, Foster City, CA, USA.
  • Mulato A; Gilead Sciences, Foster City, CA, USA.
  • Hansen D; Gilead Sciences, Foster City, CA, USA.
  • Singer E; Gilead Sciences, Foster City, CA, USA.
  • Tsai LK; Gilead Sciences, Foster City, CA, USA.
  • Bam RA; Gilead Sciences, Foster City, CA, USA.
  • Chou CH; Gilead Sciences, Foster City, CA, USA.
  • Canales E; Gilead Sciences, Foster City, CA, USA.
  • Brizgys G; Gilead Sciences, Foster City, CA, USA.
  • Zhang JR; Gilead Sciences, Foster City, CA, USA.
  • Li J; Gilead Sciences, Foster City, CA, USA.
  • Graupe M; Gilead Sciences, Foster City, CA, USA.
  • Morganelli P; Gilead Sciences, Foster City, CA, USA.
  • Liu Q; Gilead Sciences, Foster City, CA, USA.
  • Wu Q; Gilead Sciences, Foster City, CA, USA.
  • Halcomb RL; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Saito RD; Gilead Sciences, Foster City, CA, USA.
  • Schroeder SD; Gilead Sciences, Foster City, CA, USA.
  • Lazerwith SE; Terns Pharmaceuticals, Foster City, CA, USA.
  • Bondy S; Gilead Sciences, Foster City, CA, USA.
  • Jin D; Vir Biotechnology Inc, San Francisco, CA, USA.
  • Hung M; Gilead Sciences, Foster City, CA, USA.
  • Novikov N; Gilead Sciences, Foster City, CA, USA.
  • Liu X; Gilead Sciences, Foster City, CA, USA.
  • Villaseñor AG; Gilead Sciences, Foster City, CA, USA.
  • Cannizzaro CE; Gilead Sciences, Foster City, CA, USA.
  • Hu EY; Gilead Sciences, Foster City, CA, USA.
  • Anderson RL; Gilead Sciences, Foster City, CA, USA.
  • Appleby TC; Gilead Sciences, Foster City, CA, USA.
  • Lu B; Gilead Sciences, Foster City, CA, USA.
  • Mwangi J; Gilead Sciences, Foster City, CA, USA.
  • Liclican A; Gilead Sciences, Foster City, CA, USA.
  • Niedziela-Majka A; MyoKardia Inc, South San Francisco, CA, USA.
  • Papalia GA; Gilead Sciences, Foster City, CA, USA.
  • Wong MH; Gilead Sciences, Foster City, CA, USA.
  • Leavitt SA; Gilead Sciences, Foster City, CA, USA.
  • Xu Y; Gilead Sciences, Foster City, CA, USA.
  • Koditek D; Gilead Sciences, Foster City, CA, USA.
  • Stepan GJ; Gilead Sciences, Foster City, CA, USA.
  • Yu H; Gilead Sciences, Foster City, CA, USA.
  • Pagratis N; Gilead Sciences, Foster City, CA, USA.
  • Clancy S; Gilead Sciences, Foster City, CA, USA.
  • Ahmadyar S; Gilead Sciences, Foster City, CA, USA.
Nature ; 584(7822): 614-618, 2020 08.
Article em En | MEDLINE | ID: mdl-32612233
ABSTRACT
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis1-5. However, some people living with HIV who are heavily treatment-experienced have limited or no treatment options, owing to multidrug resistance6. In addition, suboptimal adherence to oral daily regimens can negatively affect the outcome of treatment-which contributes to virologic failure, resistance generation and viral transmission-as well as of pre-exposure prophylaxis, leading to new infections1,2,4,7-9. Long-acting agents from new antiretroviral classes can provide much-needed treatment options for people living with HIV who are heavily treatment-experienced, and additionally can improve adherence10. Here we describe GS-6207, a small molecule that disrupts the functions of HIV capsid protein and is amenable to long-acting therapy owing to its high potency, low in vivo systemic clearance and slow release kinetics from the subcutaneous injection site. Drawing on X-ray crystallographic information, we designed GS-6207 to bind tightly at a conserved interface between capsid protein monomers, where it interferes with capsid-protein-mediated interactions between proteins that are essential for multiple phases of the viral replication cycle. GS-6207 exhibits antiviral activity at picomolar concentrations against all subtypes of HIV-1 that we tested, and shows high synergy and no cross-resistance with approved antiretroviral drugs. In phase-1 clinical studies, monotherapy with a single subcutaneous dose of GS-6207 (450 mg) resulted in a mean log10-transformed reduction of plasma viral load of 2.2 after 9 days, and showed sustained plasma exposure at antivirally active concentrations for more than 6 months. These results provide clinical validation for therapies that target the functions of HIV capsid protein, and demonstrate the potential of GS-6207 as a long-acting agent to treat or prevent infection with HIV.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: HIV-1 / Fármacos Anti-HIV / Proteínas do Capsídeo Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Nature Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: HIV-1 / Fármacos Anti-HIV / Proteínas do Capsídeo Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Nature Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos